Total item
Cart Subtotal
$0.00 mTOR
| Catalog No. | Inhibitor Name | mTOR | mTORC1 | mTORC2 | Other Targets |
|---|---|---|---|---|---|
| A10133 | Dactolisib | *** | p110α,p110γ,p110δ | ||
| A10782 | Rapamycin | **** | |||
| A10374 | Everolimus | *** | |||
| A10114 | AZD8055 | **** | DNA-PK,PI3Kδ,PI3Kα | ||
| A10906 | Temsirolimus | * | |||
| A10726 | PI-103 | * | p110α,p110δ,p110β | ||
| A10505 | KU-0063794 | ** | ** | ||
| A10746 | Torkinib | ** | p110δ,PDGFR,DNA-PK | ||
| A10295 | Ridaforolimus | **** | |||
| A11461 | INK 128 | **** | PI3Kα,PI3Kγ,PI3Kδ | ||
| A10997 | Voxtalisib Analogue | * | PI3Kγ,PI3Kα,PI3Kδ | ||
| A11587 | Torin 1 | *** | *** | ** | DNA-PK,p110γ,C2α |
| A11035 | Omipalisib | **** | **** | p110α,p110δ,p110γ | |
| A11056 | OSI-027 | *** | * | * | PI3Kγ,DNA-PK,PI3Kα |
| A11024 | PF-04691502 | ** | PI3Kδ,PI3Kα,PI3Kγ | ||
| A11023 | Apitolisib | * | p110α,p110δ,p110γ | ||
| A10438 | GSK1059615 | ** | PI3Kα,PI3Kβ,PI3Kδ | ||
| A11079 | Gedatolisib | **** | PI3Kα,PI3Kγ | ||
| A10989 | WYE-354 | *** | PI3Kα,PI3Kγ | ||
| A11303 | Vistusertib | *** | P-Akt (S473),pS6 (S235/236) | ||
| A11586 | Torin 2 | **** | ATM,ATR,DNA-PK | ||
| A11038 | WYE-125132 | **** | |||
| A11207 | PP121 | ** | PDGFR,Hck,VEGFR | ||
| A11187 | WYE-687 | *** | PI3Kα,PI3Kγ,p38α | ||
| A11169 | CH5132799 | * | PI3Kα,PI3Kγ,PI3Kβ | ||
| A11188 | WAY-600 | ** | PI3Kα,PI3Kγ | ||
| A13328 | ETP-46464 | **** | ATR,DNA-PK,PI3Kα | ||
| A11443 | GDC-0349 | *** | PI3Kα | ||
| A12395 | XL388 | ** | ** | * | CYP2C9,CYP3A4 |
| A13078 | CC-223 | ** | cFMS,FLT4,DNA-PK | ||
| A16276 | Voxtalisib | * | PI3Kγ,PI3Kα,PI3Kδ | ||
| A11950 | Zotarolimus | *** | |||
| A10389 | Tacrolimus | ||||
| A11162 | BGT226 | PI3Kα,PI3Kγ,PI3Kβ | |||
| A10693 | Palomid 529 | ||||
| A10210 | Chrysophanic Acid | EGFR | |||
| A11537 | QL-IX-55 | ||||
| A12480 | VS-5584 | **** | PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ | ||
| A12704 | SF1126 | PI3K | |||
| A12935 | PF-04979064 | **** | PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ, Akt | ||
| A14432 | GNE-493 | *** | PI3Kα, PI3Kδ, PI3Kγ, PI3Kβ | ||
| A15175 | mTOR inhibitor (mTOR-IN-1) | *** | |||
| A15508 | MHY1485 | ||||
| A16126 | LY3023414 | PI3Kα, Akt1, DNA-PK |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
48 Item(s)
per page
-
GSK2126458 (Omipalisib)
Catalog No. A11035 mTOR/PI3K Inhibitor,GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Learn More -
mTOR inhibitor (mTOR-IN-1)
Catalog No. A15175 mTOR inhibitormTOR inhibitor is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 1.5 nM. Learn More -
MHY1485
Catalog No. A15508 mTOR inhibitorMHY1485 is a mTOR activator; inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes. Learn More -
PF-04691502
Catalog No. A11024 PI3K/mTOR InhibitorPF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway. Learn More -
GDC-0980 (Apitolisib, RG7422)
Catalog No. A11023 mTOR/PI3K InhibitorGDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 α, β, δ and γ isoforms, respectively. Learn More -
QL-IX-55
Catalog No. A11537 mTORC1/2 inhibitorQL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC50s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively. Learn More -
LY3023414
Catalog No. A16126 PI3K/mTOR Dual InhibitorLY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242). Learn More -
BEZ235 (NVP-BEZ235, Dactolisib)
Catalog No. A10133 PI3K/mTOR InhibitorBEZ235 (NVP-BEZ235) inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Learn More -
VS-5584
Catalog No. A12480 PI3K/mTOR inhibitorVS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Learn More -
SAR245409 (XL765, Voxtalisib)
Catalog No. A16276 PI3K/mTOR dual inhibitorSAR245409 is a PI3K/mTOR dual kinase inhibitor XL765 is an orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Learn More -
Zotarolimus
Catalog No. A11950 mTOR inhibitorZotarolimus is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier. Learn More -
Torin 1
Catalog No. A11587 mTOR inhibitorTorin1 is a potent inhibitor of mTOR with IC50 of 2-10 nM. Learn More -
Torin 2
Catalog No. A11586 mTOR inhibitorTorin 2 is a potent and selective mTOR inhibitor (IC50 = 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively). Learn More -
XL388
Catalog No. A12395 mTOR inhibitorXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR). Learn More -
ETP-46464
Catalog No. A13328 ATR inhibitorETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM. Learn More -
PF-04979064
Catalog No. A12935 PI3K/mTOR Dual InhibitorPF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor. Learn More -
GDC-0349
Catalog No. A11443 mTOR inhibitorGDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Learn More -
GNE 477
Catalog No. A14114 PI3K/mTOR inhibitorGNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα, Kiapp is 21 nM for mTOR. Learn More -
GNE-493
Catalog No. A14432 Dual Pan PI3k/mTOR inhibitorGNE-493 is potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor with potential anticancer activity. Learn More -
AP1903
Catalog No. A13519 AP1903 is a lipid-permeable tacrolimus analogue with homodimerizing activity. Dimerizer drug AP1903 homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val) so that AP1903 binds to wild-type FKBP12 with 1000-fold lower affinity. Learn More -
LY 303511
Catalog No. A15147 PI3K inhibitorLY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K. Learn More -
CC-115
Catalog No. A15779 mTOR/DNA-PK inhibitorCC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM). Learn More -
CC-223
Catalog No. A13078 mTOR InhibitorCC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K-alpha (IC50=4uM). Learn More -
Desmethyl-VS-5584
Catalog No. A10900 PI3K/mTOR inhibitorDesmethyl-VS-5584 is a demethyl analogue of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Learn More -
CZ415
Catalog No. A16476 mTOR inhibitorCZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex. Learn More -
INK 128 (MLN0128)
Catalog No. A11461 mTOR inhibitorINK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity. Learn More -
AZD2014 (Vistusertib)
Catalog No. A11303 mTORC1/2 inhibitorAZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor. Learn More -
WYE-125132 (WYE-132)
Catalog No. A11038 mTOR InhibitorWYE-125132 is an ATP-competitive and specific inhibitor of mTORC1 and mTORC2 (IC50 = 0.19 nM; >5,000-fold selective versus PI3Ks). Learn More -
AZD8055
Catalog No. A10114 mTOR InhibitorAZD8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. Learn More -
Palomid 529 (P529)
Catalog No. A10693 AKT InhibitorPalomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation. Learn More -
PP242 (Torkinib)
Catalog No. A10746 mTOR InhibitorPP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2. Learn More -
KU-0063794
Catalog No. A10505 mTOR InhibitorKU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively). Learn More -
Everolimus (RAD001)
Catalog No. A10374 mTOR inhibitorEverolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an mTOR inhibitor. Learn More -
GSK1059615
Catalog No. A10438 mTOR/PI3K InhibitorGSK1059615 is a potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3Kα (IC50 = 2 nM). Learn More -
PI-103
Catalog No. A10726 PI3K InhibitorPI-103 is a potent, cell-permeable, ATP-competitive inhibitor of phosphatidylinositol 3-kinase (PI3K) family members with selectivity toward DNA-PK, PI3K (p110α), and mTOR. Learn More -
Rapamycin (Sirolimus)
Catalog No. A10782 mTOR InhibitorsRapamycin (Sirolimus) prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2). Learn More -
XL765
Catalog No. A10997 PI3K inhibitorXL765 is a PI3K/mTOR dual kinase inhibitor and it is more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone. Learn More -
OSI-027
Catalog No. A11056 mTOR inhibitorOSI-027 is a potent, selective and orally bioavailable mTOR kinase inhibitor that inhibits the kinase activity associated with both the TORC1 and TORC2 complexes of mTOR. Learn More -
FK-506 (Tacrolimus)
Catalog No. A10389 mTOR inhibitorFK-506 is an immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It reduces interleukin-2 (IL-2) production by T-cells. Learn More -
Deforolimus (Ridaforolimus)
Catalog No. A10295 mTOR InhibitorDeforolimus (Ridaforolimus) is an investigational targeted and small-molecule inhibitor of the protein mTOR. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.
Learn More -
WYE-354
Catalog No. A10989 mTOR InhibitorWYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2. It is a much weaker inhibitor of PI3K α (IC50 = 1026 nM) and other kinases. Learn More -
PP121
Catalog No. A11207 PI3K InhibitorPP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR). Learn More -
WAY-600
Catalog No. A11188 mTOR inhibitorWAY-600 is a single digit nanomolar inhibitor of the mTOR kinases, with significant selectivity for these enzymes over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold).
Learn More -
WYE-687
Catalog No. A11187 mTOR InhibitorWYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin(mTOR).
Learn More -
CH5132799
Catalog No. A11169 PI3K inhibitorCH5132799 is a novel class I PI3K inhibitor, which exhibited a strong inhibitory activity especially against PI3Kα (IC(50)=0.014 μM).
Learn More -
NVP-BGT226
Catalog No. A11162 PI3K inhibitorNVP-BGT226, novel phosphoinositide 3-kinase/mTOR dual inhibitor, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Learn More -
PKI-587 ( Gedatolisib )
Catalog No. A11079 PI3K/mTOR inhibitorPKI-587 is a highly potent PI3K/mTOR kinase inhibitor that inhibits PI3K-α,β,γ, δ isoforms and mTOR with IC50 of 0.4, 6.0, 5.4, 6.0 and 1.6 nM respectively. Learn More -
Temsirolimus (Torisel)
Catalog No. A10906 mTOR inhibitorTemsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells. Learn More
48 Item(s)
per page
Adooq Quality Guarantee
We promise all products perform as described.